AirNexis has handed over $40 million cash for Haisco’s HSK39004, coded by AirNexis as AN01. Under the terms of the deal, Haisco will hold a 19.9% equity stake in the biotech, while also earning the ...
AirNexis Therapeutics is a clinical-stage biotech company developing novel therapeutic drugs for the treatment of COPD patients. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through ...
A clinical-stage biotechnology company headquartered in Palo Alto, California. The company is focused on respiratory medicine ...
Company founded by Frazier Life Sciences, which led the Series A financing with participation from OrbiMed, Life Sciences at Goldman Sachs Alternatives, SR One, Longitude Capital and Enavate Sciences ...
Medipost's $140 million funding will accelerate late-stage clinical development of cell-based therapies for inflammatory and degenerative conditions, enhancing global trials and regulatory preparation ...
11d
Haisco Grants Global Rights of Innovative Drug HSK39004 to AirNexis in Deal Exceeding USD 1 Billion
On January 9, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with US based biotech AirNexis. Under the agreement, ...
Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions. The company is backed by experienced life science ...
Activists also report to the SEC on Vor Biopharma, Camp4 Therapeutics, and Recursion Pharmaceuticals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results